|
⚲
|
| Keyboard |
| Versant Venture Management LLC
✚
|
|
|---|---|
| CRD # | 161130 |
| SEC # | 802-75823 |
| CIK # | 0001560009 |
| AUM | |
| Employees | |
| Phone | 415-801-8100 |
| Address | One Sansome Street San Francisco, CA 94104 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($) |
|---|
| In the News | |
|---|---|
| Thu, 16 Jul 2026 | Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position — MarketBeat |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Monte Rosa Therapeutics Inc | 52.3 | ||
| Century Therapeutics Inc | 27.5 | ||
| Graphite Bio Inc | 24.3 | ||
| Aerovate Therapeutics Inc | 21.4 | ||
| Contineum Therapeutics Inc | 7.1 | ||
| CRISPR Therapeutics AG | 7.1 | ||
| LOAD Guard Logistics Inc | 1.2 | ||
| OvaScience Inc | 0.4 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Versant Venture Capital SPV I SAB LP | 2025-03-27 | 5.9 M | |
| VC | Versant Vantage III Canada LP | 2023-03-29 | 3.5 M | |
| VC | Versant Vantage III LP | [2023-03-29] | 298.7 M | 295.6 M |
| Offered $298,654,822 · Filed 2023-04-07 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Venture Capital IX Canada LP | 2023-03-29 | 7.2 M | |
| VC | Versant Venture Capital IX LP | [2023-03-29] | 600.4 M | 586.2 M |
| Offered $600,357,143 · Filed 2023-04-07 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Voyageurs III Canada LP | 2023-03-29 | 3.7 M | |
| VC | Versant Voyageurs III LP | [2023-03-29] | 300.2 M | 311.8 M |
| Offered $300,178,571 · Filed 2023-04-07 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Vantage II LP | [2021-03-30] | 253.9 M | 249.7 M |
| Offered $253,857,868 · Filed 2021-04-15 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Venture Capital VIII Canada LP | 2021-03-30 | 12.9 M | |
| VC | Versant Venture Capital VIII LP | [2021-03-30] | 560.2 M | 886.9 M |
| Offered $560,244,898 · Filed 2021-04-15 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Charles Warden | Director | 52 | 3 | |
| Kirk Nielsen | Director | 47 | 3 | |
| Camille Samuels | Director | 17 | 3 | |
| William Link | Director | 81 | 2 | |
| Brian Atwood | Director | 47 | 2 | |
| Bradley Bolzon | Director, Executive Officer | 43 | 2 | |
| Rebecca Robertson | Director | 37 | 2 | |
| Jerel Davis | Director, Executive Officer | 36 | 2 | |
| Ross Jaffe | Director | 31 | 2 | |
| Thomas Woiwode | Director, Executive Officer | 31 | 2 | |
| Clare Ozawa | Director, Executive Officer | 23 | 2 | |
| Samuel Colella | Director | 22 | 2 | |
| Donald Milder | Director | 19 | 2 | |
| Barbara Lubash | Director | 18 | 2 | |
| Carlo Rizzuto | Executive Officer | 14 | 2 | |
| Robin Praeger | Director, Executive Officer | 12 | 2 | |
| Alex Mayweg | Executive Officer | 7 | 2 | |
| Tom Woiwode | Director | 4 | 2 | |
| Versant Ventures V LLC | Director | 3 | 2 | |
| Versant Ventures VI GP LP | Director | 3 | 2 | |
| Versant Ventures VII GP LP | Director | 2 | 2 | |
| Versant Voyageurs I GP LP | Promoter | 2 | 2 | |
| Versant Ventures I LLC | Director | 3 | 1 | |
| Versant Vantage I GP LP | Director | 1 | 1 | |
| Versant Vantage III GP LP | Executive Officer | 1 | 1 | |
| Versant Voyageurs III GP LP | Executive Officer | 1 | 1 | |
| Versant Ventures VIII GP Canada LLC | Executive Officer | 1 | 1 | |
| Versant Ventures IX GP LP | Executive Officer | 1 | 1 | |
| Versant Voyageurs I GP Company | Promoter | 1 | 1 | |
| Versant Ventures IX GP Canada LLC | Executive Officer | 1 | 1 | |
| Versant Ventures II LLC | Director | 1 | 1 | |
| Versant Voyageurs III GP Canada LLC | Executive Officer | 1 | 1 | |
| Versant Vantage III GP Canada LLC | Executive Officer | 1 | 1 | |
| Versant Voyageurs II GP LP | Executive Officer | 1 | 1 | |
| Versant Vantage II GP LP | Executive Officer | 1 | 1 | |
| Versant Voyageurs II GP Canada LLC | Executive Officer | 1 | 1 | |
| Versant Ventures VIII GP LP | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001560009] | |
| 3 | [0001560009] | |
| 4 | [0001560009] |
| Related People Network |
|---|
| 44 people file Form D offerings alongside this firm's people. |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 8,614 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 145,796 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 1,303 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 2,766 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Option exercise | 118,573 | $7.55 | 895,226 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Option exercise | 1,059 | $7.55 | 7,995 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Option exercise | 2,249 | $7.55 | 16,980 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Tax withheld | 45,010 | $19.88 | 894,799 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Tax withheld | 402 | $19.88 | 7,992 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Tax withheld | 854 | $19.88 | 16,978 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 603,612 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 5,179 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 10,996 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 1,044,048 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 9,330 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 19,812 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 453,925 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 4,055 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Series D Preferred Stock · derivative
|
2012-10-16 | Conversion | 145,796 | $0.00 | |
|
Kythera Biopharmaceuticals Inc KYTH
Series D Preferred Stock · derivative
|
2012-10-16 | Conversion | 1,303 | $0.00 | |
| showing 20 of 39 most recent transactions | |||||